| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 952675 | Social Science & Medicine | 2011 | 9 Pages |
In recent years, a substantial amount of technological progress in medicine has taken the form of pharmaceutical innovation. This paper uses the launch of a series of new drugs designed for treating type 2 diabetic patients as an example to investigate the determinants that affect the diffusion of new medical technology. Based on prescription-level data that are obtained from the national health insurance program in Taiwan, we find that the probability of prescribing new drugs declines as more competing products enter the pharmaceutical market. Meanwhile, physicians are less likely to prescribe new drugs to treat their patients as the provider market becomes less concentrated. These results suggest that the providers’ incentives for cost reduction dominate incentives for quality improvement as markets become more competitive and hence an increase in market competition is associated with a decrease in the diffusion of new drugs. As a result, access to new drugs is not uniform among patients in a country with universal coverage for prescription drugs. An important implication of our study is that profit-seeking behavior among providers can become an access barrier to new medical technology.
► We investigate the effect of various economic factors on the diffusion of new drugs. ► An increase in market competition leads to a decrease in the diffusion of new drugs. ► Access to new drugs is not uniform among patients with universal coverage. ► Profit-seeking behavior among providers can become an access barrier to new drugs.
